Alzheimer's Society blog

Donanemab has been licensed in the UK as a treatment for early-stage Alzheimer’s but is only available privately, not through the NHS. Here's what we know about this new Alzheimer's drug.

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this breakthrough Alzheimer's drug.